Ritanserin in the treatment of generaliz
โ
E. A. Pangalila-Ratu Langi; A. A. I. Jansen
๐
Article
๐
1988
๐
John Wiley and Sons
๐
English
โ 381 KB
๐ 2 views
In a double-blind trial, 22 patients treated with 5 mg b.i.d. of the selective serotonin-S2 antagonist ritanserin for 4 weeks were compared with 26 patients treated with placebo for generalized anxiety disorder (DSM 111: 300.02). Symptoms were assessed using the Hamilton Anxiety Rating Scale (HARS)